SCHEMBL4711079

SCHEMBL4711079

O=[C]SCCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.45
CYP2D6 P10635 2/20 0.45
CYP2C19 P33261 2/20 0.45
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
CASP1 P29466 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CA2 P00918 3/20 0.44
KEAP1 Q14145 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
CYP2A6 P11509 1/20 0.42
HTR2A P28223 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
NOS1 P29475 1/20 0.42
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28515 0.78 CTSL (0.43) CYP1A2CYP2D6CYP2C19ALDH1A1HSD17B10
SCHEMBL10986671 0.76 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C19ALDH1A1HPGD
SCHEMBL2936984 0.76 MAOA (0.50) CYP1A2CYP2D6CYP2C19ALDH1A1HPGD
SCHEMBL11683822 0.73 CYP1A2 (0.52) CYP1A2CYP2D6CYP2C19ALDH1A1HPGD
SCHEMBL7604988 0.72 MAOA (0.50) ALDH1A1HPGDALOX15ALOX12CASP1
SCHEMBL43326 0.72 MAOA (0.50) ALDH1A1HPGDALOX15ALOX12CASP1
SCHEMBL11344362 0.72 MAOA (0.50) ALDH1A1HPGDALOX15ALOX12CASP1
SCHEMBL2059225 0.71 CYP1A2 (0.41) CYP1A2CYP2D6CYP2C19ALDH1A1HPGD
SCHEMBL577806 0.71 CYP1A2 (0.76) CYP1A2CYP2D6CYP2C19ALDH1A1HPGD
SCHEMBL4185660 0.71 ALDH1A1 (0.55) CYP1A2CYP2D6CYP2C19ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7402595-B2 Enzyme inhibitors with isoquinolinone structures TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-22 US disclosed
US-20050148624-A1 Jnk inhibitor TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-07-07 US disclosed
EP-1484320-A1 JNK INHIBITOR Takeda Chemical Industries, Ltd. (JP) 2004-12-08 EP disclosed
US-5475008-A Selective non-competitive antagonists of n-methyl-d-aspartate receptors MERCK SHARP & DOHME LIMITED (GB) 1995-12-12 US disclosed
EP-0459561-B1 Dioxo-tetrahydroquinoline derivatives MERCK SHARP & DOHME (GB) 1995-09-20 EP disclosed
EP-0614363-A1 QUINOLONE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1994-09-14 EP disclosed
US-5268378-A Oxo group in 2 and 4 position MERCK SHARP & DOHME, LIMITED (GB) 1993-12-07 US disclosed
WO-1993010783-A2 QUINOLONE DERIVATIVES AND THEIR USE AS AMPA AND NMDA RECEPTOR ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 1993-06-10 WO disclosed
EP-0459561-A2 Dioxo-tetrahydroquinoline derivatives MERCK SHARP & DOHME LTD. (GB) 1991-12-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148624-A1 Jnk inhibitor MAPK3, MAPKAPK3, MAPK1 CYP1A2 1839/4885CYP2D6 2177/4885CYP2C19 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.